Literature DB >> 28830286

Anticoagulation of Percutaneous Ventricular Assist Device Using Argatroban-Based Purge Solution: A Case Series.

Emily C Blum1, Carolyn R Martz1, Yelena Selektor2, Hassan Nemeh3, Zachary R Smith1, Long To1.   

Abstract

Impella devices are percutaneously inserted ventricular assist devices which require a continuous purge solution that contains heparin to prevent pump thrombosis and device failure. We describe 2 patients with heparin-induced thrombocytopenia (HIT) supported with an Impella device utilizing an argatroban-based purge solution. Case 1 involved an 83-year-old female with biventricular failure which resulted in right ventricle Impella support. The purge solution was changed to include argatroban due to concern of device clotting in the setting of HIT. Case 2 involved a 55-year-old male with worsening cardiogenic shock which resulted in left ventricle Impella support. Due to decreased purge flow rates and concerns for clotting, argatroban was added to the purge solution. Both patients' total argatroban regimens were monitored and adjusted by pharmacy, resulting in therapeutic anticoagulation without any major bleeding or thrombotic events. Subsequently, a protocol was designed and implemented. These case reports appear to demonstrate the safe and effective use of argatroban purge solutions for the necessary anticoagulation with an Impella device. Further studies are needed to confirm these results and determine the optimal dosing regimen.

Entities:  

Keywords:  anticoagulation; cardiology; critical care

Mesh:

Substances:

Year:  2017        PMID: 28830286     DOI: 10.1177/0897190017727191

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  7 in total

Review 1.  Management of Anticoagulation with Impella® Percutaneous Ventricular Assist Devices and Review of New Literature.

Authors:  Luma Succar; Elisabeth M Sulaica; Kevin R Donahue; Matthew A Wanat
Journal:  J Thromb Thrombolysis       Date:  2019-08       Impact factor: 2.300

2.  Therapeutic Anticoagulation With an Ultra-Low Concentration Argatroban-Based Purge Solution for Percutaneous Ventricular Assist Device in Patient With Heparin-Induced Thrombocytopenia.

Authors:  Andrea Sikora Newsome; Ashley Taylor; Seth Garner
Journal:  Hosp Pharm       Date:  2019-12-07

Review 3.  Outcomes of percutaneous temporary biventricular mechanical support: a systematic review.

Authors:  Matthew P Weber; Thomas J O'Malley; Jae H Choi; Elizabeth J Maynes; Kyle W Prochno; Melissa A Austin; Chelsey T Wood; Sinal Patel; Rohinton J Morris; H Todd Massey; Vakhtang Tchantchaleishvili
Journal:  Heart Fail Rev       Date:  2022-05       Impact factor: 4.214

4.  The Effects of the Combined Argatroban/Nitric Oxide-Releasing Polymer on Platelet Microparticle-Induced Thrombogenicity in Coated Extracorporeal Circuits.

Authors:  Tiffany R Bellomo; Mark A Jeakle; Mark E Meyerhoff; Robert H Bartlett; Terry C Major
Journal:  ASAIO J       Date:  2021-05-01       Impact factor: 3.826

5.  Survey of Anticoagulation Practices with the Impella Percutaneous Ventricular Assist Device at High-Volume Centers.

Authors:  Brent N Reed; Robert J DiDomenico; J Erin Allender; James C Coons; Jenna F Cox; Daniel Johnson; Carrie S Oliphant; Douglas L Jennings
Journal:  J Interv Cardiol       Date:  2019-03-04       Impact factor: 2.279

6.  Evaluation of Thrombocytopenia in Patients Receiving Percutaneous Mechanical Circulatory Support With an Impella Device.

Authors:  Erin A Houry; Brooke E Gengler; Justin L Alberts; Joseph S Van Tuyl
Journal:  Crit Care Explor       Date:  2022-10-07

7.  Heparin-Induced Thrombocytopenia under Mechanical Circulatory Support by Large Impella for Acute Cardiogenic Shock.

Authors:  Yukiharu Sugimura; Sebastian Bauer; Moritz Benjamin Immohr; Derik Franz Hermsen; Ralf Westenfeld; Udo Boeken; Hug Aubin; Igor Tudorache; Artur Lichtenberg; Payam Akhyari
Journal:  J Cardiovasc Dev Dis       Date:  2021-11-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.